-
2008
12 February 2008: Press release no. 1, 2008: Phase III program for AVE0010/ZP10 licensed ...
-
Product Pipeline
Pipeline with 1 compound in phase III, 2 compounds in phase II, 3 compounds in phase I and ...
-
Available Positions
We have one vacant position: Scientist-Department of Molecular Pharmacology ...
GAP-134/ZP1609
GAP-134/ZP1609, a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.
GAP-134/ZP1609 prevents postoperative AF and chronic AF in large animal models. In a canine model of acute sterile pericarditis, GAP-134/ZP1609 significantly reduced AF duration and overall AF burden. In a canine model of heart failure, induced by dual chamber simultaneous pacing of the right atria and right ventricle, GAP-134/ZP1609 significantly reduced mean AF duration, number of AF episodes and inducibility. This canine heart failure model is designed to mimic patients in the early stages of heart failure presenting with AF requiring cardioversion and chronic maintenance of sinus rhythm therapy.
GAP-134/ZP1609 may provide a safe and well-tolerated treatment option for atrial fibrillation patients with or without structural heart disease or heart failure, for whom the long-term maintenance of normal sinus rhythm is the strategy of choice thereby providing patients an improved quality of life.
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.